PBMA's H. V. Desai Eye Hospital

Clinical Trials

Sponsor- Lux Bioscience
Project Name:-

1. LX201-01.- A multi center, placebo –controlled, randomized, Parallel-group, Dose Ranging study to access the efficacy and safety of LX201 for prevention of corneal Allograft Rejection episodes and graft failure following penetrating ketatoplsty with LX 201 implantation in subjects who are at increased immunological Risk.
2. LX 201-02- A multi center, placebo –controlled, randomized, Parallel-group, Dose Ranging study to access the efficacy and safety of LX201 for the prevention of corneal allograft rejection episodes Or Graft failure in subjects who experienced one or more rejection episodes following penetrating keraoplasty.
Sponsor-Sun Pharma Advance Research Company

3. Comparison of the efficacy and safety of Latanoprost 0.005% (Xalatan ® Reference) and Latanoprost 0.005% administered once daily in open angle glaucoma and ocular hypertension.
Sponsor- Thea Laboratories

4. Efficacy and safety assessment of T2345 unpreserved eye drops versus Xalatan in Ocular Hypertensive or Glaucomatous Patients.

Sponsor-Sun Pharma Advance Research Company

1. Study to evaluate Safety of Benzalkonium Chloride Free Latanoprost Ophthalmic Solution 0.005% in Subjects with Glaucoma.

Sponsor: - International Diabetes federation

2. International Diabetic research project “Welcome Genetics of diabetics” (Welgen) in collaboration with KEMH-DU
3. Unraveling the Genetic Basis of Glaucoma in India with Genome Wide SNP Microarrays and DNA Pooling (SNP-Map)
4. Randomized control trial for comparative evaluation of sutureless vitrectomy and pan retinal photocoagulation in proliferative diabetic retinopathy with localized vitreous hemorrhage.